Levomilnacipran

From Wikipedia, the free encyclopedia - View original article

Levomilnacipran
Levomilnacipran.svg
Levomilnacipran3DanJ.gif
Systematic (IUPAC) name
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
Clinical data
Trade namesFetzima
Pregnancy cat.C (US)
Legal status Prescription only
RoutesOral
Pharmacokinetic data
Protein binding22%
MetabolismHepatic (primarily by CYP3A4)
Half-life12 hours
ExcretionRenal
Identifiers
CAS number96847-55-1 YesY
175131-60-9 (hydrochloride)
ATC codeNone
PubChemCID 6917779
ChemSpider5293005 N
UNIIUGM0326TXX YesY
KEGGD10072 N
Chemical data
FormulaC15H22N2O 
Mol. mass246.348 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Levomilnacipran
Levomilnacipran.svg
Levomilnacipran3DanJ.gif
Systematic (IUPAC) name
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
Clinical data
Trade namesFetzima
Pregnancy cat.C (US)
Legal status Prescription only
RoutesOral
Pharmacokinetic data
Protein binding22%
MetabolismHepatic (primarily by CYP3A4)
Half-life12 hours
ExcretionRenal
Identifiers
CAS number96847-55-1 YesY
175131-60-9 (hydrochloride)
ATC codeNone
PubChemCID 6917779
ChemSpider5293005 N
UNIIUGM0326TXX YesY
KEGGD10072 N
Chemical data
FormulaC15H22N2O 
Mol. mass246.348 g/mol
 N (what is this?)  (verify)

Levomilnacipran (brand name Fetzima) is an antidepressant approved for the treatment of major depressive disorder in the United States. It was developed by Forest Laboratories and Pierre Fabre Group, and was approved by the Food and Drug Administration in July 2013.[1] Levomilnacipran is the levo- enantiomer of milnacipran, and has similar effects pharmacology, acting as a serotonin-norepinephrine reuptake inhibitor (SNRI).[2][3]

The FDA approved the product in July 2013 based on the results of one 10-week Phase 2 and four 8-week phase III clinical trials. Four of the five trials demonstrated a statistically significant superiority to placebo as measured by the Montgomery-Ashberg Depression Rating Scale. Superiority to placebo was also demonstrated by improvement in the Sheehan Disability Scale. Important side effects included blood pressure increases, nausea/vomiting, sweating, constipation, erectile dysfunction in men, and heart rate increases.[1]

References[edit]

  1. ^ a b Citrome L (November 2013). "Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?". Int. J. Clin. Pract. 67 (11): 1089–104. doi:10.1111/ijcp.12298. PMID 24016209. 
  2. ^ "Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression - FierceBiotech". 
  3. ^ Deprez D, Chassard D, Baille P, Mignot A, Ung HL, Puozzo C (1998). "Which bioequivalence study for a racemic drug? Application to milnacipran". European Journal of Drug Metabolism and Pharmacokinetics 23 (2): 166–71. doi:10.1007/bf03189334. PMID 9725476.